NCT04746131View on ClinicalTrials.gov

Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL)

PHASE1SuspendedINTERVENTIONAL

Enrollment

90

Participants

Timeline

Start Date

January 15, 2021

Primary Completion Date

April 11, 2024

Study Completion Date

April 11, 2024

Conditions

B-cell Non-Hodgkin's Lymphoma

Interventions

DRUG

IMM0306

IMM0306 is an bi-specific antibody

Trial Locations (1)

45219

The Christ Hospital, Cincinnati

Sponsors

Collaborators (1)

Worldwide Clinical Trials

All Listed Sponsors

collaborator

Worldwide Clinical Trials

OTHER

lead

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

OTHER